NRT6008 + chemotherapy

NRT6008 + chemotherapy is an experimental combination therapy under clinical study for the treatment of unresectable locally advanced pancreatic cancer. NRT6008 is administered as an injection in combination with standard systematic chemotherapy. The investigational agent NRT6008 is described as a small molecule drug and may consist of Yttrium-90 carbon microspheres, suggesting a radiopharmaceutical mechanism, though the precise chemical structure or detailed mechanism of NRT6008 is not publicly disclosed. The combination is intended to enhance the efficacy of chemotherapy by targeting tumor tissues more effectively, potentially overcoming local disease progression. The primary objective in current trials is to establish the safety profile and preliminary efficacy of this combination. The sponsor and originator is Chengdu New Radiomedicine Technology Co.,Ltd[1][2][4].

Other names

Yttrium-90 carbon microspheres + systematic chemotherapy